Market Cap 42.16M
Revenue (ttm) 11.00M
Net Income (ttm) -69.78M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -634.36%
Debt to Equity Ratio 0.00
Volume 1,706,500
Avg Vol 1,132,590
Day's Range N/A - N/A
Shares Out 58.72M
Stochastic %K 54%
Beta 1.03
Analysts Sell
Price Target $10.00

Company Profile

BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC to treat melanoma and squamous cell carcinoma o...

Industry: Biotechnology
Sector: Healthcare
Phone: 858 558 0708
Fax: 858 558 0709
Address:
11085 Torreyana Road, San Diego, United States
miguelgarfer
miguelgarfer Oct. 25 at 7:43 PM
$BCAB I've decided to double my position in Bioatla. I'm clear about the situation and have complete confidence. I believe the potential gains versus the potential losses are crystal clear.
0 · Reply
BiotechValues
BiotechValues Oct. 25 at 3:30 PM
$BCAB https://x.com/Bullstkpicks/status/1981928904920351140
0 · Reply
onemillion2012
onemillion2012 Oct. 25 at 8:00 AM
$BCAB just the beginning
0 · Reply
deni_mimi
deni_mimi Oct. 24 at 4:10 PM
$BCAB ..monday bo?
0 · Reply
BiotechValues
BiotechValues Oct. 24 at 2:25 PM
$BCAB nice strength today. Seems like some smart money realizing the potential of the EpCAM data upside. Also feels like another day closer to D (ph3 deal) Day.
1 · Reply
SPYmyQQQ
SPYmyQQQ Oct. 24 at 2:19 PM
🎯 Target Hit 🏁 📨 From Oct 21, 2025 💊 $BCAB 💵 Entry: $0.6726 ✅ Exit: $0.7868 💰 P/L: +16.98% 👉 FREE TRIAL! spymyqqq/join/
0 · Reply
shortkiller7
shortkiller7 Oct. 24 at 9:00 AM
$BCAB Compare the difference between the two news! (10/23 vs 9/8) 1. The worldwide market opportunity for 2nd line plus OPSCC is over $1.X billion and for 1st line HPV+ tumors is potentially over $7 billion. 2. The prognosis is currently poor for patients with recurrent/metastatic OPSCC who have previously received standard treatments including surgery, radiation, platinum-based chemotherapy, and PD-1 inhibitor therapy. 3. Company continues preparations for enabling initiation of the Phase 3 study with the goal of advancing the study with a strategic partner in early 2026. Waht it means! LO is comming!
2 · Reply
Misterx69
Misterx69 Oct. 23 at 7:49 PM
0 · Reply
pankooo
pankooo Oct. 23 at 6:06 PM
$BCAB 1Q/2026 TP 3,2 usd
0 · Reply
jjrrjjrr
jjrrjjrr Oct. 23 at 2:57 PM
$BCAB 🤫🤫
0 · Reply
Latest News on BCAB
BioAtla, Inc. (BCAB) Q2 2025 Earnings Call Transcript

Aug 9, 2025, 2:43 AM EDT - 2 months ago

BioAtla, Inc. (BCAB) Q2 2025 Earnings Call Transcript


BioAtla, Inc. (BCAB) Q1 2025 Earnings Call Transcript

May 6, 2025, 5:55 PM EDT - 6 months ago

BioAtla, Inc. (BCAB) Q1 2025 Earnings Call Transcript


BioAtla to Participate in the Citizens Life Sciences Conference

Apr 30, 2025, 8:00 AM EDT - 6 months ago

BioAtla to Participate in the Citizens Life Sciences Conference


BioAtla, Inc. (BCAB) Q4 2024 Earnings Call Transcript

Mar 27, 2025, 6:18 PM EDT - 7 months ago

BioAtla, Inc. (BCAB) Q4 2024 Earnings Call Transcript


BioAtla Cuts 30% of Jobs in Restructuring Effort

Mar 27, 2025, 5:05 PM EDT - 7 months ago

BioAtla Cuts 30% of Jobs in Restructuring Effort


BioAtla, Inc. (BCAB) Q3 2024 Earnings Call Transcript

Nov 9, 2024, 8:53 AM EST - 1 year ago

BioAtla, Inc. (BCAB) Q3 2024 Earnings Call Transcript


BioAtla: Numerous Catalysts Coming In Q4

Oct 7, 2024, 11:29 AM EDT - 1 year ago

BioAtla: Numerous Catalysts Coming In Q4


BioAtla, Inc. (BCAB) Q2 2024 Earnings Call Transcript

Aug 11, 2024, 1:32 AM EDT - 1 year ago

BioAtla, Inc. (BCAB) Q2 2024 Earnings Call Transcript


BioAtla, Inc. (BCAB) Q1 2024 Earnings Call Transcript

May 14, 2024, 8:35 PM EDT - 1 year ago

BioAtla, Inc. (BCAB) Q1 2024 Earnings Call Transcript


BioAtla: A Buried ADC Concern Gets Some New Life In 2024

May 2, 2024, 10:03 AM EDT - 1 year ago

BioAtla: A Buried ADC Concern Gets Some New Life In 2024


BioAtla, Inc. (BCAB) Q4 2023 Earnings Call Transcript

Mar 26, 2024, 7:21 PM EDT - 1 year ago

BioAtla, Inc. (BCAB) Q4 2023 Earnings Call Transcript


miguelgarfer
miguelgarfer Oct. 25 at 7:43 PM
$BCAB I've decided to double my position in Bioatla. I'm clear about the situation and have complete confidence. I believe the potential gains versus the potential losses are crystal clear.
0 · Reply
BiotechValues
BiotechValues Oct. 25 at 3:30 PM
$BCAB https://x.com/Bullstkpicks/status/1981928904920351140
0 · Reply
onemillion2012
onemillion2012 Oct. 25 at 8:00 AM
$BCAB just the beginning
0 · Reply
deni_mimi
deni_mimi Oct. 24 at 4:10 PM
$BCAB ..monday bo?
0 · Reply
BiotechValues
BiotechValues Oct. 24 at 2:25 PM
$BCAB nice strength today. Seems like some smart money realizing the potential of the EpCAM data upside. Also feels like another day closer to D (ph3 deal) Day.
1 · Reply
SPYmyQQQ
SPYmyQQQ Oct. 24 at 2:19 PM
🎯 Target Hit 🏁 📨 From Oct 21, 2025 💊 $BCAB 💵 Entry: $0.6726 ✅ Exit: $0.7868 💰 P/L: +16.98% 👉 FREE TRIAL! spymyqqq/join/
0 · Reply
shortkiller7
shortkiller7 Oct. 24 at 9:00 AM
$BCAB Compare the difference between the two news! (10/23 vs 9/8) 1. The worldwide market opportunity for 2nd line plus OPSCC is over $1.X billion and for 1st line HPV+ tumors is potentially over $7 billion. 2. The prognosis is currently poor for patients with recurrent/metastatic OPSCC who have previously received standard treatments including surgery, radiation, platinum-based chemotherapy, and PD-1 inhibitor therapy. 3. Company continues preparations for enabling initiation of the Phase 3 study with the goal of advancing the study with a strategic partner in early 2026. Waht it means! LO is comming!
2 · Reply
Misterx69
Misterx69 Oct. 23 at 7:49 PM
0 · Reply
pankooo
pankooo Oct. 23 at 6:06 PM
$BCAB 1Q/2026 TP 3,2 usd
0 · Reply
jjrrjjrr
jjrrjjrr Oct. 23 at 2:57 PM
$BCAB 🤫🤫
0 · Reply
BiotechValues
BiotechValues Oct. 23 at 1:57 PM
$BCAB https://ir.bioatla.com/news-releases/news-release-details/bioatla-presents-compelling-mechanistic-rationale-targeting-ror2 Stage getting set for ph3 start. Also guidance remains unchanged regarding timing/partnership (from today's PR)
1 · Reply
shortkiller7
shortkiller7 Oct. 23 at 12:48 PM
$BCAB If that mechanism is proven, a first-line treatment in HPV HNSCC challenge is possible. Keytruda combination therapy, so Merck will love it. 7b$ market value...
0 · Reply
shortkiller7
shortkiller7 Oct. 23 at 12:17 PM
$BCAB big deal is comming!
0 · Reply
BigPennyStockAlerts
BigPennyStockAlerts Oct. 23 at 12:07 PM
$BCAB BioAtla Presents Compelling Mechanistic Rationale for Targeting ROR2 with Ozuriftamab Vedotin (Oz-V) in Oropharyngeal Squamous Cell Carcinoma (OPSCC) at the Annual Conference of the International Papillomavirus Society
0 · Reply
onemillion2012
onemillion2012 Oct. 23 at 12:07 PM
$BCAB new poster out. See homepage
0 · Reply
shortkiller7
shortkiller7 Oct. 23 at 6:30 AM
$BCAB merck right now!
0 · Reply
winners18
winners18 Oct. 22 at 3:45 PM
$BCAB another adc deals
0 · Reply
shortkiller7
shortkiller7 Oct. 22 at 12:40 PM
$BCAB odds of BioAtla CAB-ADC (6.5-7/10) Strengths: Safety Advantage: Conditional activation of CAB can reduce normal tissue toxicity (especially gastrointestinal tract). e.g. Grade 3+ TRAEs 49.7% of IBI343 vs. 30% or less of CAB-ADC assumptions. Efficacy Potential: BioAtla's CAB-ADC (ORR 30-40% based on BA3021) is similar ORR expectation in CLDN18.2, low expression patient cover with bystander effect. DIFFERENTIATION: Existing ADCs (e.g., IBI343, AZD0901) are always toxic with active antibodies, and CAB can be positioned as next-generation ADCs with microenvironmental specificity. Market Opportunity: CLDN18.2 Market Expects USD 9.7 Billion In 2030, ADC Advantages Late Line/Monotherapy Over Zolbetuximab (mAb).
0 · Reply
shortkiller7
shortkiller7 Oct. 22 at 12:33 PM
$BCAB In conclusion, CAB is a highly suitable technology for addressing the toxicity issue of CLDN18.2 ADC, which, if developed by BioAtla, could have a competitive advantage
0 · Reply
shortkiller7
shortkiller7 Oct. 22 at 12:32 PM
$BCAB CLDN18.2 is overexpressed in gastric cancer (60–80%) and pancreatic cancer (50%), but GI toxicity in conventional ADCs is a problem due to limited expression in the normal gastrointestinal tract. CAB can address this issue. Currently, CLDN18.2 ADC (e.g., IBI343, CMG901) reduces toxicity with glycan-based or Fc-silenced designs, but like CAB, environment-dependent activation is more innovative. Although BioAtla has not yet released CLDN18.2 CAB-ADC, it is technically compatible, and BioAtla's platform is being applied to various targets (AXL, ROR2).
0 · Reply
shortkiller7
shortkiller7 Oct. 22 at 12:22 PM
$BCAB Another big ADC deal! https://www.reuters.com/business/healthcare-pharmaceuticals/chinas-innovent-signs-114-billion-cancer-therapy-deal-with-japans-takeda-2025-10-22/
0 · Reply
onemillion2012
onemillion2012 Oct. 22 at 7:38 AM
$NERV $BCAB can't wait until Bioalta secure capital. For the phase 3 asset. Nerv sold at $2.11 to investors. And now $6. So if Bioalta get a partnership whitout rapping shareholders with new shares Then we get a 300 percent day.
2 · Reply